BioNTech successfully tests a cancer vaccine

BioNTech announces successful trials of a cancer vaccine. Ugur Sahin, one of the founders of BioNTech, spoke about this, reports CNN Turk.

The plan is to have study data for a range of other therapeutic approaches between 2025 and 2029, he said.

Sahin hopes that the first personalized mRNA-based cancer vaccines will be approved by 2030.

“We take blood and tumor samples from the patient, and after four weeks we give an individual vaccine… Ideally, it’s not 100, but thousands of patients a year,” he says.

Last month, the company announced results from its first clinical trial of a combination of an mRNA cancer vaccine and CAR T cell therapy. Tumors stopped growing in almost all patients and shrank in about two-thirds.

“In this approach, the immune system will deliberately seek out and destroy the tumor with the help of an army of special fighters,” says Shahin.

He added that the strategy for the future is combination therapy using different techniques.

“I am confident that in the next few years, ADCS (antibody drug conjugates – ed.) will increasingly become targeted chemotherapy over traditional chemotherapy in various cancer settings,” said Sahin.

We remind you that the pharmaceutical companies Pfizer/BioNTech have tested a COVID vaccine directed against the Omicron strain.

It was also reported that the European Commission entered into an agreement with a number of pharmaceutical companies, including the American company Pfizer, to reserve capacity for the annual production of 325 million vaccines in the event of a humanitarian emergency.